Immunotherapy Coverage from Every Angle
Advertisement
Advertisement

Recent News

Treatment Duration for Nivolumab in Advanced NSCLC: CheckMate 153
Case Study: Chemoimmunotherapy Combination in Merkel Cell Carcinoma
Adding Zanubrutinib to Obinutuzumab in CLL
Adding Daratumumab to Carfilzomib-Based Therapy in Resistant Myeloma: CANDOR Trial
Immunochemotherapy Primed With Oncolytic Vaccinia Virus in Platinum-Resistant Ovarian Cancer
ESMO 2020: Does Immune Oncology Increase the Risk of SARS-CoV2–Related Mortality in NSCLC?
Early Use of Lenalidomide With Pneumococcal Vaccine for High-Risk CLL
Autoimmune Dermatosis in a Pembrolizumab-Treated Patient With Merkel Cell Carcinoma: Case Study
Post-Hoc Analysis of Belantamab Mafodotin in Resistant Myeloma From DREAMM-2
ESMO 2020: Pembrolizumab Versus Docetaxel in Subgroup of Patients With NSCLC
ESMO 2020: Lenvatinib Plus Pembrolizumab in Metastatic Thyroid Carcinoma
ESMO 2020: Vinorelbine Plus Atezolizumab in Recurrent Stage IV Lung Cancer
EBCC 12: Long-Term Survival Outcomes From Phase III Trial in HER2-Positive Breast Cancer
COVID-19, Merkel Cell Carcinoma, and Immunotherapy: Case Study
ESMO 2020: First-Line Pembrolizumab, Chemotherapy, and Lenvatinib in Metastatic NSCLC
ESMO 2020: Adding Atezolizumab to Chemotherapy Under Study in Triple-Negative Breast Cancer
SOHO 2020: Cross-Study Comparison of Carfilzomib, Dexamethasone, and Daratumumab Dosing Regimens in Myeloma
IGCS 2020: Lenvatinib Plus Pembrolizumab in Ovarian Cancer
ESMO 2020: Can Immunotherapy Enhance Effects of Chemotherapy in Triple-Negative Breast Cancer?
SOHO 2020: Interim Analysis of Real-World Registry of Elderly Patients With CLL
ESMO 2020: Adding Pembrolizumab After Enzalutamide Failure in Prostate Cancer
ESMO 2020: Combining Ipilimumab With PD-1 Blockade in Advanced Lung Cancer
How Exercise May Impact Natural Killer Cells in Patients With Prostate Cancer
Bone Marrow Involvement From Merkel Cell Carcinoma: Case Study
SOHO 2020: Debulking Regimens Prior to Venetoclax Therapy for CLL
SOHO 2020: Fixed-Volume Isatuximab in Resistant Multiple Myeloma
ESMO 2020: Targeting PD-1 in Merkel Cell Carcinoma
SOHO 2020: Chemotherapy-Free Combination Therapy for CLL Under Study in Phase III Trial
SOHO 2020: Predicting Treatment-Free Remission With Nilotinib in Chronic-Phase CML
IGCS 2020: Maintenance Immunotherapy for Stage III or IV Ovarian Cancer
Transplant-Ineligible Myeloma: Comparing Regimens With and Without Daratumumab
NPM1‐Mutant AML and COVID-19: Modified Protocols for Monitoring Treatment Response
Combination Therapy for BRAF-Mutant Thyroid Cancer: Preclinical Model
High-Risk CLL: Hematopoietic Stem Cell Transplantation Followed by Immune Intervention
Effects of Immunosuppression in Merkel Cell Carcinoma
Copyright © 2020 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.